Leadless pacemaker technology: clinical evidence of new paradigm of pacing

Rev Cardiovasc Med. 2022 Jan 25;23(2):43. doi: 10.31083/j.rcm2302043.

Abstract

Despite continuous technological developments, transvenous pacemakers (PM) are still associated with significant immediate and long-term complications, mostly lead or pocket-related. Recent technological advances brought to the introduction in clinical practice of leadless PM for selected cohort of patients. These miniaturize devices are implanted through the femoral vein and advanced to the right ventricle, without leaving leads in place. Lack of upper extremity vascular access and/or high infective risk in patients requiring VVI pacing are the most common indications to leadless PM. The recently introduced MICRA AV leadless PM also allows ventricular synchronization through mechanical sensing of atrial contraction waves, thus solving the problem of AV synchronization. This review will discuss and summarize available clinical evidence on leadless PM, their performance compared to transvenous devices, current applications and future perspectives.

Keywords: Leadless pacing; MICRA; Nanostim; Transvenous pacing.

Publication types

  • Review

MeSH terms

  • Cardiac Pacing, Artificial* / adverse effects
  • Equipment Design
  • Heart Ventricles
  • Humans
  • Pacemaker, Artificial*